

December 17, 2019
 Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director,
 President and Chief Executive Officer

**Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses)
 Issued by way of Third Party Allotment**

TOKYO, Japan, December 17, 2019—Symbio Pharmaceuticals Limited announces the large volume exercise of the 47th Stock Acquisition Rights, issued and allotted to EVO FUND on April 25, 2018, during the period from December 2, 2019 to December 17, 2019, as below.

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 47 th Stock Acquisition Rights
(2)	Number of issued shares from the beginning of this month	400,000 Shares
(3)	Number of stock acquisition rights being exercised from the beginning of this month and the ratio to the entire issue	1,600,000 Units (Ratio to the total number of stock acquisition rights issued 15,000,000 units : 10.67%)
(4)	Number of unexercised stock acquisition rights as of the beginning of this month	11,200,000 Units
(5)	Number of remaining unexercised stock acquisition rights as of today	9,600,000 Units

(6) Exercise status from the beginning of this month

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
December 2 (Mon) ~December 4 (Wed)	—	—	621	—
December 5 (Thu) ~December 11 (Wed)	—	—	609	—
December 12 (Thu)	200,000	—	603	800,000
December 13 (Fri)	-	—	603	—
December 16 (Mon)	100,000	—	603	400,000
December 17 (Tue)	100,000	—	603	400,000

※Number of issued shares at the end of the previous month : 25,312,681 shares [of which 21,018 shares are treasury shares]

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.